Viewing nowCombinationDuoStar Tablet 40/5 mg
Telmisartan 40mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.

MFDS item code 201906992 · Approved 2019.09.30 · Insurance code 693903130
Treatment of hypertension and dyslipidemia; prevention of cardiovascular disease; inhibition of atherosclerosis progression
This medication is used for patients who need to take telmisartan and rosuvastatin together. Telmisartan primarily treats essential hypertension and helps reduce the risk of myocardial infarction, stroke, and mortality due to cardiovascular disease in elderly patients at high risk. Rosuvastatin is used in patients with hypercholesterolemia and mixed dyslipidemia to lower blood cholesterol levels in conjunction with a dietary regimen and to slow the progression of atherosclerosis. The combination of these two medications contributes to overall cardiovascular health improvement.
This medicine should be administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; depending on the patient, 20 mg once daily may be effective. If necessary, the dose may be increased to 80 mg once daily. When administered concomitantly with thiazide diuretics such as hydrochlorothiazide, this medicine produces an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
This medication can cause serious harm to the fetus and newborn if administered to pregnant women; therefore, it should be discontinued immediately upon confirmation of pregnancy. This medication should not be used by individuals who are allergic to this drug or its components, pregnant or potentially pregnant women, or nursing mothers. Patients with severe liver dysfunction or problems with bile excretion should use this medication with caution. Patients with muscle disorders or a history of muscle-related side effects and those with severe renal impairment should generally avoid this medication. This medication should be administered cautiously in elderly patients, patients with hyperkalemia, and those with mild to moderate liver dysfunction, as excessively low blood pressure may cause issues with the heart or brain. If symptoms such as muscle pain, muscle weakness, or muscle cramps occur during the use of this medication, you should consult your physician immediately and, if necessary, check muscle enzyme levels; if abnormalities are found, use should be discontinued. Regular monitoring of liver function tests is required, and if liver function abnormalities worsen, use should be stopped. Since there may be drug interactions, inform your doctor or pharmacist of any other medications you are currently taking. This medication may cause drowsiness or dizziness during driving or machine operation, so caution is advised. Keep out of reach of children and change the medication container only when necessary.
headache, postural dizziness, sleep paralysis, elevated blood pressure, decreased blood pressure, hypotension, elevated ALT, dysuria, rhinitis, discomfort in the oropharynx, lung disease, unspecified gastrointestinal disorder, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, fainting, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal bloating, vomiting, abdominal discomfort, dry mouth, abnormal liver function, hepatic impairment, increased sweating, itching, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, low back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute kidney failure, chest pain, weakness, influenza-like illness, increased serum creatinine, elevated serum uric acid, increased liver enzymes, elevated serum CK, decreased hemoglobin, angioedema, hypovolemia including angioedema-associated hypersensitivity reactions, diabetes, constipation, nausea, pancreatitis, pruritus, rash and urticaria, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ophthalmoplegia, facial spasms, sensory disturbance, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, appetite loss, arrhythmia, numbness, chest discomfort, abdominal distension, fainting, generalized pain, muscle cramps, gout
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to protect it from air and moisture. It is recommended to maintain a storage temperature between 1 and 30 degrees Celsius.
Bright pink oval film-coated tablet
30 tablets/box [10 tablets/PTP*3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationTelmisartan 40mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
CombinationTelmisartan 80mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhannanghang Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhan Corporation Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.